Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | SPHK1 | Q9NYA1 | 11/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.32 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.32 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.31 |
| ▸ | SPHK2 | Q9NRA0 | 5/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20313627 | 0.97 | CYP2C9 (0.36) | CYP2C9SPHK1ALDH1A1LMNAMAPT | |
| SCHEMBL20313516 | 0.93 | CYP2C9 (0.37) | CYP2C9SPHK1ALDH1A1LMNAMAPT | |
| SCHEMBL19855538 | 0.93 | CYP2C9 (0.37) | CYP2C9SPHK1ALDH1A1LMNAMAPT | |
| SCHEMBL19722414 | 0.91 | SPHK1 (0.42) | CYP2C9SPHK1ALDH1A1LMNAMAPT | |
| SCHEMBL19722155 | 0.91 | SPHK1 (0.42) | CYP2C9SPHK1ALDH1A1LMNAMAPT | |
| SCHEMBL19755066 | 0.91 | SPHK1 (0.42) | CYP2C9SPHK1ALDH1A1LMNAMAPT | |
| SCHEMBL19854205 | 0.90 | FFAR4 (0.32) | DGAT1SOAT1 | |
| SCHEMBL19722420 | 0.90 | SPHK1 (0.41) | CYP2C9SPHK1ALDH1A1LMNAMAPT | |
| SCHEMBL19856151 | 0.90 | FFAR4 (0.31) | DGAT1P2RY14SOAT1 | |
| SCHEMBL19722404 | 0.88 | FFAR4 (0.37) | CYP2C9SPHK1ALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180179443-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2018-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180179443-A1 | POLYMERIZABLE POLAR COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | C1S, CCND1, C5 | CYP2C9 3375/4885SPHK1 212/4885ALDH1A1 2615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.